SMS PHARMACEUTICALS LTD.

SMS Pharmaceuticals Ltd has provided an update on the police complaint filed regarding the claiming of shares through impersonation. Following an investigation, one individual allegedly involved has been arrested and produced before the court for judicial remand. The company stated that the matter is under further investigation and reiterated its commitment to safeguarding shareholder interests through appropriate legal and regulatory actions.

SMS Pharmaceuticals Ltd has responded to a clarification sought by the exchange regarding recent volume and price movements in its scrip. The company stated that it has been in full compliance with SEBI regulations, promptly disclosing all material and price-sensitive information. SMS Pharmaceuticals clarified that there are no pending announcements or events that could impact the stock's behavior. The company attributes the recent price movement solely to market conditions and market-driven factors.

SMS Pharmaceuticals Ltd has announced the closure of its trading window for dealing in the company's shares. This closure is effective from July 1st, 2026, and will remain in effect until 48 hours after the declaration of financial results for the first quarter ended June 30th, 2026. The decision aligns with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The specific date for the board meeting to consider these financial results will be communicated later. This measure is intended to prevent potential insider trading activities.

SMS Pharmaceuticals Ltd has uncovered a fraudulent scheme involving the impersonation of shareholders to claim 85,000 equity shares held in physical form. The company's investigation revealed forged KYC documents and a consistent modus operandi used to fraudulently transfer shares belonging to seven original shareholders. Following the advice of its Stakeholders Relationship Committee, the company has filed a complaint with the Economic Offences Wing (EOW) in Hyderabad, which has registered a case for further investigation. SMS Pharmaceuticals is committed to protecting shareholder interests and will pursue all necessary legal and regulatory actions.

SMS Pharmaceuticals Ltd reported a 48% YoY increase in PAT to ₹102 crore for FY26, driven by backward integration and product mix. EBITDA margin expanded by 155 bps YoY to 19%. Revenue grew by 13% YoY to ₹886.87 crore. The company's board recommended a final dividend of ₹0.40 per share. SMS Pharma anticipates over 15% revenue growth with EBITDA margins around 20% in FY27. VKT Pharma, an associate company, contributed ₹14 crores to the FY26 PAT.

SMS Pharmaceuticals Ltd's board approved the audited financial results for the year ended March 31, 2026. The company reported revenue from operations of ₹886.87 million and a net profit of ₹2.43 million. The board recommended a final dividend of ₹0.40 per equity share. Additionally, the registered office is being shifted within Hyderabad, and M/s. Annapragada & Co. is appointed as Cost Auditors for FY27.

SMS Pharmaceuticals Ltd's board approved the audited financial results for the year ended March 31, 2026. The company reported revenue from operations of ₹886.87 million and a net profit of ₹2.43 million. The board recommended a final dividend of ₹0.40 per equity share (40%) for FY26, subject to shareholder approval. Additionally, the registered office is being shifted within Hyderabad, and auditors have been appointed/re-appointed for FY27.

SMS Pharmaceuticals Ltd's board approved the audited financial results for the year ended March 31, 2026. The company reported revenue from operations of ₹886.87 Cr and a net profit of ₹2.43 Cr. The board recommended a final dividend of ₹0.40 per equity share. They also approved the re-appointment of M/s. Adusumilli & Associates as Internal Auditors and the appointment of M/s. Annapragada & Co. as Cost Auditors for FY 2026-27. Additionally, the registered office is being shifted within Hyderabad.

SMS Pharmaceuticals Ltd. announced a final dividend of ₹0.40 per equity share (40%) for the financial year 2025-26, subject to member approval at the AGM. The board also approved the audited financial results for the fourth quarter and year ended March 31, 2026, and shifting of the registered office. Additionally, M/s. Annapragada & Co. was appointed as Cost Auditors and M/s. Adusumilli & Associates re-appointed as Internal Auditors for FY 2026-27.

SMS Pharmaceuticals Ltd. announced audited financial results for the year ended March 31, 2026. Key highlights include revenue from operations of ₹886.87 million and a net profit of ₹2.43 million. The board recommended a final dividend of ₹0.40 per equity share. Additionally, the company approved the shifting of its registered office and the appointment/re-appointment of auditors.